CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) Major Shareholder Sells $148,424.88 in Stock

CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) major shareholder Bioventures Opportunities G. Yk sold 1,236,874 shares of the firm’s stock in a transaction on Friday, December 6th. The stock was sold at an average price of $0.12, for a total value of $148,424.88. Following the transaction, the insider now owns 21,383,909 shares in the company, valued at $2,566,069.08. This trade represents a 5.47 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Major shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

CERo Therapeutics Price Performance

Shares of NASDAQ:CERO opened at $0.07 on Friday. The company’s fifty day moving average is $0.13 and its two-hundred day moving average is $0.22. CERo Therapeutics Holdings, Inc. has a 1-year low of $0.06 and a 1-year high of $12.80.

CERo Therapeutics Company Profile

CERo Therapeutics Holdings, Inc, an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.